retatrutide trial update october 2025 Investigational weight-loss drug shows average reduced body weight of 30% retatrutide approval status october 2025

Maintaining weight loss after stopping treatment One question that too few telehealth providers address upfront is what happens when you stop taking the medication

Why compounded and not brand-name

06.17.25 21 plaintiffs asked for consolidation in case against Novo Nordisk A group of New Jersey plaintiffs asked the state court to consolidate their cases into a multicounty litigation

doi: 10.1016/j.jand.2018.05.019

Protein shakes designed for GLP-1 users offer a convenient way to maintain intake when appetite is heavily suppressed

Jastreboff AM et al., SURMOUNT-1, NEJM 2022 (NEJMoa2206038) : tirzepatide up to 15 mg, loss -22,5% at 72 weeks